Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6574709 | 0.78 | CES2 (0.41) | EPHX1CES2CES1HDAC8HDAC6 | |
| SCHEMBL800571 | 0.78 | CES2 (0.36) | EPHX1CES2CES1HDAC8HDAC6 | |
| SCHEMBL990465 | 0.78 | CES2 (0.36) | EPHX1CES2CES1HDAC8HDAC6 | |
| SCHEMBL1651118 | 0.76 | CES2 (0.39) | EPHX1CES2CES1HDAC8HDAC6 | |
| SCHEMBL5003950 | 0.73 | CD81 (0.36) | ALOX5LMNACYP2D6 | |
| SCHEMBL25234936 | 0.72 | LMNA (0.38) | EPHX1ALOX5LMNACYP2D6 | |
| SCHEMBL464872 | 0.72 | LMNA (0.38) | EPHX1ALOX5LMNACYP2D6 | |
| SCHEMBL16267791 | 0.72 | LMNA (0.38) | EPHX1ALOX5LMNACYP2D6 | |
| SCHEMBL9090277 | 0.72 | LMNA (0.38) | EPHX1ALOX5LMNACYP2D6 | |
| SCHEMBL1770285 | 0.72 | LMNA (0.38) | EPHX1ALOX5LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4204406-A1 | ENRICHMENT OF A DIASTEREOMER IN MAGNOLAN | Symrise AG (DE) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022042829-A1 | ENRICHMENT OF A DIASTEREOMER IN MAGNOLAN | SYMRISE AG (DE) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043089-A1 | ENRICHMENT OF A DIASTEREOMER IN MAGNOLAN | SYMRISE AG (DE) | 2022-03-03 | — | — | WO | disclosed |
| EP-3167031-A1 | ISOMER MIXTURES OF UNSATURATED MACROCYCLIC MUSK COMPOUNDS | Symrise AG (DE) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016005360-A1 | MIXTURES HAVING ENRICHED E-ISOMERS OF UNSATURATED MACROCYCLIC MUSK COMPOUNDS | SYMRISE AG (DE) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016005361-A1 | ISOMER MIXTURES OF UNSATURATED MACROCYCLIC MUSK COMPOUNDS | SYMRISE AG (DE) | 2016-01-14 | — | — | WO | disclosed |
| US-20070037733-A1 | Use of 3-cyclohexenyl-1-propanol as a fragrance | SYMRISE GMBH & CO. KG (DE) | 2007-02-15 | — | — | US | disclosed |
| EP-1260572-B1 | High-purity cyclopentanone derivatives, process for preparing same, and perfume composition | ZEON CORP (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20050009928-A1 | Cyclopentanone derivative | ZEON CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1420005-A1 | CYCLOPENTANONE DERIVATIVE | Zeon Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6653276-B2 | A cyclopentanone or cyclopentanol compound having 2,5-dicyclopentylidene substituents, 2,5- dicyclopentyl substituents or 2-cyclopentylidene-5-cyclopentyl substituents; useful as perfume emitting floral fragrance | ZEON CORPORATION (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20030012799-A1 | High-purity cyclopentane compound having oxygen-containing group, process for preparing same, and perfume composition | ZEON CORPORATION (JP) | 2003-01-16 | — | — | US | disclosed |
| EP-1260572-A1 | High-purity cyclopentanone derivatives, process for preparing same, and perfume composition | Zeon Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | PTGIS, CYP51A1, TRPA1 | EPHX1 1386/4885CES2 278/4885CES1 489/4885 |
| US-20030012799-A1 | High-purity cyclopentane compound having oxygen-containing group, process for preparing same, and perfume composition | DHPS, DOHH, PORCN | EPHX1 1079/4885CES2 580/4885CES1 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.